Whether peptidases present in vascular cells can activate prodrugs active on vascular cells has been tested with 2 potential latent ligands of the histamine H 1 receptor (H 1 R). First, a peptide consisting of the antihistamine cetirizine (CTZ) condensed at the N-terminus of ε-aminocaproyl-bradykinin (εACA-BK) was evaluated for an antihistamine activity that could be revealed by degradation of the peptide part of the molecule. CTZ-εACA-BK had a submicromolar affinity for the BK B 2 receptor (B 2 R; IC 50 of 590 nM, [ The human umbilical vein contractility assay responded to L-alanyl-histamine (EC 50 54.7 µM), but the APN inhibitor amastatin massively (17-fold) reduced its apparent potency. Amastatin did not influence the potency of histamine as a contractile agent. One of the 2 tested latent H 1 R ligands, Lalanyl-histamine, supported the feasibility of pro-drug activation by vascular ectopeptidases.